Evidence map›Paper›PMID 24951759›Full record

ReviewCirculation research2014

Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Kavita Sharma, David A Kass

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 4 pooled it
31.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 4 syntheses or guidelines pooled it, 489 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cellular basis of HFpEF: contributions of abnormal lipids.Frontiers in cardiovascular medicine · 2026
    Review
  18. Review
  19. Article
  20. Review

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kavita SharmaFrom the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.
David A KassFrom the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD. dkass@jhmi.edu.
Johns Hopkins University · US

Funding

Pathobiology of Cardiac Dyssynchrony &ResynchronizationP01HL077180 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI VAN EYK, JENNIFER E · 2004 to 2014
$22.8M
PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Chulan Kwon, WENDY S POST · 1985 to 2026
$21.2M
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAHR01HL114910 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M. · 2012 to 2023
$6.2M
PKG Redox Modulation of Cardiac Function and DiseaseR01HL119012 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2013 to 2016
$1.6M
NHLBI NIH HHS HL077180NHLBI NIH HHS HL114910NHLBI NIH HHS HL119012NHLBI NIH HHS P01 HL077180NHLBI NIH HHS R01 HL114910NHLBI NIH HHS R01 HL119012NHLBI NIH HHS T32 HL007227NHLBI NIH HHS T32HL07227
6 · The paper itself

Abstract

The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the predominant form of HF in the developed world, and soon to reach epidemic proportions. It remains among the most challenging of clinical syndromes for the practicing clinician and scientist alike, with a multitude of proposed mechanisms involving the heart and other organs and complex interplay with common comorbidities. Importantly, its morbidity and mortality are on par with HF with reduced EF, and as the list of failed treatments continues to grow, HF with preserved EF clearly represents a major unmet medical need. The field is greatly in need of a more unified approach to its definition and view of the syndrome that engages integrative and reserve pathophysiology beyond that related to the heart alone. We need to reflect on prior treatment failures and the message this is providing, and redirect our approaches likely with a paradigm shift in how the disease is viewed. Success will require interactions between clinicians, translational researchers, and basic physiologists. Here, we review recent translational and clinical research into HF with preserved EF and give perspectives on its evolving demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that involve the heart and other organs, clinical trials, and future directions.

Indexed as

Cyclic GMP-Dependent Protein KinasesDiastoleEnergy MetabolismExercise TherapyHeart FailureHumansHypertension, PulmonaryInflammationMuscle, SkeletalStroke VolumeSystoleVentricular Function, LeftCyclic GMP-Dependent Protein Kinasesdiastoleheart failurehypertensionhypertrophytherapy

Identifiers

PMID24951759
PMCPMC4146618
OpenAlexW2527933700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.